El Boussadani B, Benajiba C, Aajal A, Ait Brik A, Ammour O, El Hangouch J, Oussama O, Oussama B, Tahiri N, Raissuni Z
Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc.
Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc.
Ann Cardiol Angeiol (Paris). 2020 May;69(3):107-114. doi: 10.1016/j.ancard.2020.04.001. Epub 2020 Apr 7.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过血管紧张素受体感染宿主细胞,导致与COVID-19相关的肺炎。该病毒对心血管系统有双重影响,如果宿主有心血管合并症,感染会更严重,且该病毒可导致危及生命的心血管病变。与COVID-19相关的治疗可能会产生不良心血管影响。因此,在COVID-19感染期间应特别关注心血管保护。